Bcl-2 Inhibitor GDC-0199
Phase 2Small molecule
Bcl-2 Inhibitor GDC-0199 is one of 52 small molecule programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
87 competitors in Chronic Lymphocytic Leukemia
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Gazyva
RochePhase 3
Calquence
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Brukinsa
BBeOne Medicines
Phase 3
Keytruda
Merck & Co.Phase 3
Beqalzi
BBeOne Medicines
Phase 3
Adcetris
PfizerPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 2
Nemtabrutinib
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bcl-2 Inhibitor GDC-0199. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKerry Rogers